Skip to main content
Purple Biotech Ltd. logo

Purple Biotech Ltd. — Investor Relations & Filings

Ticker · PPBT ISIN · IL0007650166 TA Manufacturing
Open in API
Filings indexed 1,071 across all filing types
Latest filing 2025-02-03 Report Publication Anno…
Country IL Israel
Listing TA PPBT

About Purple Biotech Ltd.

https://purple-biotech.com/

Purple Biotech Ltd. is a clinical-stage company that develops first-in-class therapies for cancer patients. The company focuses on advancing treatments designed to overcome tumor immune evasion and drug resistance, with the goal of providing effective and durable therapeutic solutions.

Recent filings

Filing Released Lang Actions
Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform
Report Publication Announcement Classification · 98% confidence The document is a filing from Purple Biotech Ltd, identified as a 'Foreign Corporation' reporting to the Israel Securities Authority and the Tel Aviv Stock Exchange. The filing is titled '6K: Purple Biotech Announces Research Collaboration...' and explicitly states, 'Attached hereto is a report on*6K: Purple Biotech Announces Research Collaboration...*'. The document length is short (2254 chars) and its primary function is to announce the publication of an attached report (likely an SEC Form 6-K, which is a general report for foreign private issuers). According to Rule 2, when a document is short and announces the publication of another report, it should be classified as a Report Publication Announcement (RPA).
2025-02-03 English
6K- ATM
Regulatory Filings Classification · 95% confidence The document explicitly identifies itself as a "FORM 6-K" and a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934". Form 6-K filings are used by foreign private issuers to report material information to the SEC, often on a current basis, similar to a Form 8-K in the US. This type of filing does not map directly to the provided definitions (10-K, IR, ER, etc.). Since Form 6-K is a general, current report required by the SEC for foreign issuers that doesn't fit the specific categories like Annual Report (10-K), Interim Report (IR), or Earnings Release (ER), the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as the general category for miscellaneous SEC filings that do not fit elsewhere. *Self-Correction/Refinement*: While RNS is the fallback, the content specifically details an update regarding an At-The-Market (ATM) offering program, which relates to capital raising/financing activities. However, the document *form* is the primary identifier here. Given the strict definitions, and the fact that Form 6-K is a general regulatory filing mechanism, RNS is the safest classification unless the content strongly suggests CAP (Capital/Financing Update). Since the core purpose of the document is to fulfill a periodic SEC reporting requirement for material events (Form 6-K), RNS is chosen as the general regulatory filing category.
2025-01-07 English
6K- ATM
Report Publication Announcement Classification · 98% confidence The document is very short (1986 characters) and explicitly states, "Attached hereto is a report on *6K: ATM* ea0226945-6k_purplebioEDGAR2_Bannerless_isa.pdf". This structure—a brief announcement referencing an attached or linked external report—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. The filing mentions the Israel Securities Authority and the Tel Aviv Stock Exchange, and references a '6K' form, which is an SEC filing type often used by foreign private issuers, but the document itself is the announcement of that filing, not the full 6K content. Therefore, RPA is the most appropriate classification.
2025-01-07 English
PROSPECTUS SUPPLEMENT (to Prospectus Supplement dated October 17, 2023, to Prospectus dated May 22, 2023)
Capital/Financing Update Classification · 98% confidence The document explicitly states it is a 'PROSPECTUS SUPPLEMENT' filed pursuant to 'Rule 424(b)(5)' and references a 'Registration No. 333-268710'. Form 424B5 is a specific SEC filing used to register securities offerings, typically related to capital raising or sales under an existing shelf registration (like Form F-3, which is mentioned). This type of filing relates directly to the offering and sale of securities, which falls under the category of Capital/Financing Update (CAP) or potentially a specific type of registration filing. Since the definitions provided do not have a specific code for a 424B5 Prospectus Supplement, we must choose the closest fit. The document details the offering of 'American Depositary Shares' and updates the maximum offering amount under a 'Sales Agreement'. This is fundamentally a financing activity. Therefore, 'CAP' (Capital/Financing Update) is the most appropriate classification among the given options, as it describes the core purpose of the filing (updating the terms of a securities offering). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS) because it is highly specific to a capital transaction.
2025-01-06 English
PROSPECTUS SUPPLEMENT (to Prospectus Supplement dated October 17, 2023, to Prospectus dated May 22, 2023)
Capital/Financing Update Classification · 95% confidence The document is an 'Immediate report on other matter' from PURPLE BIOTECH LTD, filed with the Israel Securities Authority and Tel Aviv Stock Exchange. The key content explicitly mentions a 'PROSPECTUS SUPPLEMENT' and references previous prospectus documents. A Prospectus Supplement is a document related to the offering or sale of securities, which falls under financing activities or capital structure changes. This aligns best with the 'Capital/Financing Update' category (CAP). Although it references attachments, the core subject matter is the financing document itself, not just the announcement of its publication, making CAP more specific than RPA or RNS.
2025-01-06 English
Purple Biotech Corporate Presentation December 2024
Investor Presentation Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is a 'Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934'. Form 6-K filings are used by foreign private issuers to report material information to the SEC, often mirroring the type of information that would be filed on a Form 8-K in the US. The content describes the availability of an 'updated Company Presentation' (Exhibit 99.1) and includes extensive forward-looking statements and corporate highlights typical of investor materials. A 'Company Presentation' is a detailed presentation for investors focusing on financials, strategy, and market position. This aligns perfectly with the definition of an Investor Presentation (IP). Although the filing itself is a Form 6-K (which might suggest RNS or LTR if it were a general announcement), the *substance* being reported and attached is clearly an Investor Presentation. Since 'Investor Presentation' (IP) is a specific category provided, it is the most accurate classification for the core material being disseminated via the 6-K wrapper. The document length is substantial (39,482 chars), indicating it is the presentation itself, not just a brief announcement of publication (which would favor RPA/RNS).
2024-12-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.